| Business Summary | | Guilford
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
engaged
in
the
development
and
commercialization
of
novel
products
in
two
principal
areas,
targeted
and
controlled
drug
delivery
systems
using
proprietary
biodegradable
polymers
for
the
treatment
of
cancer
and
other
diseases,
and
therapeutic
and
diagnostic
products
for
neurological
diseases
and
conditions.
The
Company's
first
product
in
its
drug
delivery
business
is
GLIADEL
Wafer,
a
novel
treatment
for
glioblastoma
multiforme.
The
Company
is
also
engaged
in
the
research
and
development
of
small
molecules
that
regenerate
damaged
nerves
or
protect
nerves
from
damage
for
potential
treatment
of
a
range
of
neurodegenerative
diseases
and
conditions,
such
as
Parkinson's
disease,
Alzheimer's
disease,
stroke,
Amyotrophic
Lateral
Sclerosis
(ALS),
multiple
sclerosis,
spinal
cord
injury
and
peripheral
neuropathies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GLFD
is
a
biopharmaceutical
company
engaged
in
the
development
and
commercialization
of
products
in
two
principal
areas:
targeted
and
controlled
drug
delivery
systems
and
therapeutic
and
diagnostic
products.
For
the
six
months
ended
6/30/01,
revenues
fell
7%
to
$7.9
million.
Net
loss
before
accounting
change
rose
95%
to
$32.7
million.
Revenues
reflect
the
absence
of
contract
sales.
Higher
loss
also
reflects
increased
distribution
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Craig Smith, M.D., 54 Pres,
CEO and Chairman | $660K | David Wright Exec. VP, Commercial Operations | -- | Andrew Jordan, 52 Sr.
VP, Treasurer and CFO | 302K | Thomas Seoh, 42 Sr.
VP, Gen. Counsel, Sec. | 296K | John Brennan, 57 Sr.
VP- Technical Operations and Gen. Mang.- Drug Delivery Bus. | 324K | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|